The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $45.75

Today's change+0.54 +1.19%
Updated July 28 4:00 PM EDT. Delayed by at least 15 minutes.
 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $45.75

Today's change+0.54 +1.19%
Updated July 28 4:00 PM EDT. Delayed by at least 15 minutes.

Bio-Reference Laboratories Inc up (U.S.)$0.54

Bio-Reference Laboratories Inc closed up Tuesday by (U.S.)$0.54 or 1.19% to (U.S.)$45.75. Over the last five days, shares have gained 4.43% and are currently 3.66% off of the 52-week high. Shares have outperformed the S&P 500 by 41.04% during the last year.

Key company metrics

  • Open(U.S.) $45.40
  • Previous close(U.S.) $45.21
  • High(U.S.) $46.20
  • Low(U.S.) $44.55
  • Bid / Ask-- / --
  • YTD % change+42.39%
  • Volume333,828
  • Average volume (10-day)427,616
  • Average volume (1-month)500,574
  • Average volume (3-month)618,080
  • 52-week range(U.S.) $26.32 to (U.S.) $47.49
  • Beta0.77
  • Trailing P/E25.18×
  • P/E 1 year forward23.46×
  • Forward PEG1.49×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.82
Updated July 28 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+5.74%

Based on its net profit margin of 5.74%, Bio-Reference Laboratories Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.54%Sector:HealthcareIndustry:Healthcare Facilities
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedApr 30, 201504/30/2015Jan 31, 201501/31/2015Oct 31, 201410/31/2014Jul 31, 201407/31/2014
Revenue224209228222
Total other revenue--------
Total revenue224209228222
Gross profit9990107102
Total cost of revenue125119121120
Total operating expense205197197194
Selling / general / administrative78767573
Research & development--------
Depreciation / amortization2221
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income19123128
Interest income (expense), net non-operating-1-1-1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax18123027
Income after tax1071815
Income tax, total851212
Net income1071815
Total adjustments to net income--------
Net income before extra. items1071815
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1071815
Inc. avail. to common incl. extra. items1071815
Diluted net income1071815
Dilution adjustment--------
Diluted weighted average shares28282828
Diluted EPS excluding extraordinary itemsvalue per share0.380.240.660.55
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share0.380.240.660.55